Cholesterol absorption inhibition: A strategy for cholesterol-lowering therapy

International Journal of Clinical Practice

Volumn 55, Issue 10, 2001, Pages 710-716

  Miettinen, T A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL; CHYLOMICRON; ESTER DERIVATIVE; EZETIMIBE; FATTY ACID; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; PHYTOSTEROL; SAPONIN; STEROL; SUCROSE POLYESTER; TRIACYLGLYCEROL;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIET; DIET THERAPY; DRUG RESPONSE; DRUG TOLERABILITY; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; RISK; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 0035659780     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma levels on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
3. Downs JR. Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998:279: 1615-1622.
4. The Long-Term Intervention with Pravastatin in Ischemie Disease (L1PID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
5. Sacks FM. Moyé LA. Davis BR et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation 1998: 97: 1446-1452.
6. Battula SB. Fitzsimons O. Moreno S et al. Postprandial apolipoprotein B48- and BlOO-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceide metabolism? Metabolism 2000; 49: 1049-1054.
7. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
8. Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 111). JAMA 2001; 285: 2486-2497.
9. Ros E. Intestinal absorption of triglyceride and cholesterol: dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 2000: 151: 357-359.
10. Vuoristo M. Micttinen TA. Absorption and metabolism of cholesterol. In: Christophe AB. De Vriese S, Eds. Fat digestion and absorption. Champaign, Illinois: AOCS Press, 2000; 244-275.
11. van Heek M. Parley C, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide. SCH60663. Br J Pharrnacol 2000; 129: 1748-1754.
12. Miettinen TA. Detection of changes in human cholesterol metabolism. Ann Clin Res 1970: 2: 300-320.
13. Björkhem I, Miettinen TA. Reihner E et al. Correlation between serum levels of some cholesterol precursors and activity of HMG-Co reductase in human liver. J Lipid Res 1987: 28: 1137-1143.
14. Dietschy JM, Turley SD. Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637-1659.
15. Brewer HB Jr. Lipid and lipoprotein metabolism. In: Rifkind BM, Ed. Drug treatment ofhyperlipidemia. New York: Marcel Dekker, 1991.
16. Havel RJ. Origin, metabolic fate, and metabolic function of plasma lipoproteins. In: Steinberg D, Olefsky JM. Eds. Hvpercholeslerolemiu and atherosclerosis: pathogenesis and prevention. New York: Churchill Livingstone, 1987.
17. Beisiegcl U. Lipoprotein metabolism. Eur Heart J 1998; 19(suppl A): A20-A23.
18. Weintraub M. Charach G, Grosskopf I. Disturbances in dietary fat metabolism and their role in the development of atherosclerosis. Hiomed Pharmacother 1997; 51: 311-313.
19. Russell DW. Cholesterol synthesis and metabolism. Curdiovasc Drugs Ther 1992:6: 103-110.
20. Angelin B, Einarsson K, Hellström K. Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res 1978: 19: 1017-1024.
21. Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982; 31: 438-444.
22. Miettinen TA. Strandberg TE. Gylling H. Noncholcsterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vase Biol 2000:20: 1340-1346.
23. Stamler J. Shekelle R. Dietary cholesterol and human coronary heart disease: the epidemiologic evidence. Arch Pathol Lab Med 1988; 112: 1032-1040.
24. Shekelle RB. Shryock AM. Paul O et al. Diet, serum cholesterol, and death from coronary heart disease: the Western Electric study. N Engl J Med 1981:304: 65-70.
25. Cohn JS. Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins. Can J Cardiol 1998; 14(suppl B): 18B-27B.
26. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceridc-rich remnant lipoproteins. Clin Chem 1995: 41: 153-158.
27. Mamo JCL. Atherosclerosis as a post-prandial disease. Endocrinol Metab 1995; 2: 229-244.
28. Mamo JCL, Proctor SD. Smith D. Retention of chylomicron remnants by arterial tissue: importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998; 141(suppl 1): S63-S69.
29. Rajaratnam RA, Gylling H. Miettinen TA. Impaired postprandial clearance of scalene and apolipoprotein B-48 in postmenopausal women with coronary artery disease. Clin Sei 1999; 97: 183-192.
30. Vanhanen H, Kesäniemi YA, Miettinen TA. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal sterols. and cholesterol absorption in man. Metabolism 1992; 41: 588-595.
31. Vanhanen HT. Miettinen TA. Cholesterol absorption and synthesis during pravastatin, genifibroz.il and their combination. Atherosclerosis 1995; 115: 135-146.
32. Auvverx J, Schoonjans K Fruchait JC, Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of apo C-1II genes by activating the nuclear receptor PPAR. Atherosclerosis 1996: 124(suppl): S29-S37.
33. Grundy SM, Ahrens EH Jr. Salen G et al. Mechanism of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 1972; 13: 531-551.
34. McNamara DJ. Davidson NO. Samuel P. Ahrens EH Jr. Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine.y Lipid Res 1980:21: 1058-1064.
35. Pollak OJ. Kritchevsky D. Sitosterol. In: Clarkson TB, Kritchevsky D, Pollak OJ. Eds. Monographs on atherosclerosis, vol 10. Basel: Karger, 1981; 1-219.
36. Vanhanen H, Miettinen TA. Effects of sitostanol esters, dissolved in dietary oil. on serum cholesterol, plant sterols and cholesterol precursors. Circulation 1991; 84: 11-601.
37. Miettinen TA, Gylling H. Regulation of cholesterol metabolism by dietary plant sterols. Curr Opin Lipidol 1999; 10: 9-14.
38. Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total and LDL-cholesterol concentrations in normocholesterolemic and mildly hypercholesterolemic subjects. Eur J Clin Nutr 1998; 52: 334-343.
39. Miettinen TA, Puska P, Gylling H et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N EnglJ Med 1995:333: 1308-1312.
40. Miettinen TA, Vuoristo M, Gylling H. Plant sterols regulate absorption and serum levels of different sterols. In: Christophe AB, De Vries S, Eds. Fat digestion and absorption. Champaign, IL: AOCS Press, 2000; 276-286.
41. Gylling H, Miettinen TA. The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis 1995; 117: 305-308.
42. Gylling H, Rajaratnam R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Circulation 1997; 96: 4226-4231.
43. Law M. Plant sterol and stanol margaines and health. BMJ 2000; 320: 861-864.
44. Grouse JR, Grundy SM, Johnson JH. Effects of AOMA on cholesterol metabolism in man. Metabolism 1982; 31: 733-739.
45. Bertolotti M, Spady DK. Inhibition of intestinal cholesterol absorption by surfomer (alpha-olefin maleic acid) affects hepatic cholesterol synthesis and low density lipoprotein transport in hamsters fed fat-enriched diet. Digest Liver Dis 2001 ; 33: 145-150.
46. Grouse JR, Grundy SM. Effects of sucrose polyester on cholesterol metabolism in man. Metabolism 1979; 28: 994-1000.
47. Jandacek RJ, Ramirez MM, Grouse JR. Effects of partial replacement of dietary fat by olestra on dietary cholesterol absorption. Metabolism 1990; 39: 848-852.
48. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21(suppl 3): S12-S23.
49. Lingarde F. The effect of orlistat on body weight and coronary heart dis-ease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245-254.
50. Brown WV. Novel approaches to lipid lowering: what is on the horizon? Am J Cardiol 2001 ; 87(5 suppl 1): 23B-27B.
51. Knopp RH, Bays H, Manion CV et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atherosclerosis 2001. In press.
52. Davis HR, Compton DS, Hoos L, Tetzloff G. Ezetimibe (SCH58235) inhibits cholesterol absorption, reduces plasma cholesterol, and inhibits the development of atherosclerosis in Apo E knockout mice fed a cholesterolfree diet. Eur Heart J 2000; 21(suppl): 631.
53. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor ezetimibe decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001 ; 415: 79-84.
54. Lipka LJ, LeBeaut AP, Veltri EP et al. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): pooled analysis of two phase II studies. J Am Coll Cardiol 2000; 35(2 suppl A): 257A.
55. Kosoglou T, Meyer I, Musiol B et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis 2000; 151: 135.
56. Patel SB, Salen G, Hideka H et al. Mapping a gene involved in regulating dietary cholesterol absorption: the sitosterolemia locus is found at chromosome 2p21. J Clin Invest 1998; 102: 1041-1044.
57. Salen G, Xu G, Tints OS et al. Hyperabsorption and retention of campesterol in a sitosterolemic homozygote: comparison with her mother and three control subjects. J Lipid Res 2000; 41: 1883-1889.
58. Krauss RM, Eckel RH, Howard B et al. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102: 2284-2299.
59. Miettinen TA, Gylling H. Serum non-cholesterol sterols in patients with coronary heart disease during cholesterol lowering by synthesis inhibitors. Circulation 2000: 102(suppl): 2-283.
60. Lee M-H, Lu K, Patel SB. Genetic basis of sitosterolemia. Curr Opin Lipidol200l; 12: 141-149.